MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ...
MedPage Today on MSN1d
End of the Road for Immune Checkpoint Inhibitors in Prostate Cancer?Adding an immune checkpoint inhibitor (ICI) to chemotherapy for advanced prostate cancer failed to improve survival as ...
A 68-year-old man with prostate cancer develops penile metastases, a rare but serious complication, reinforcing the need for ...
Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by ...
Researchers evaluated links between lifestyle and dietary index scores and risk of death in a prospective, multiethnic cohort of men diagnosed with non-metastatic prostate cancer.
The WOLVERINE study analyzed five trials and found metastasis-directed therapy -- primarily radiation -- may delay castration ...
Zydus Lifesciences Ltd has received final approval from the USFDA to manufacture 60 mg Apalutamide tablets for prostate ...
Prostate cancer remains one of the most commonly diagnosed cancersworldwide, with 1.4 million new cases and over 375,000 ...
Educating physicians about PSA reduction goals may increase the number of patients with mCSPC receiving first-line treatment ...
Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback